OCT-ICAS: Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis

Sponsor
jiaoliqun (Other)
Overall Status
Recruiting
CT.gov ID
NCT05550077
Collaborator
(none)
400
1
93.5
4.3

Study Details

Study Description

Brief Summary

To evaluate the clinical significance of optical coherence tomography (OCT) in interventional treatment of intracranial atherosclerotic stenosis (ICAS).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Optical Coherence Tomography
  • Procedure: Percutaneous transluminal angioplasty and stenting

Detailed Description

Stroke was the second leading cause of death worldwide and the leading cause of death in China in 2017. ICAS accounted for 10% to 15% of ischemic stroke in Western countries, and as much as 46.6%in Asia in 2009.

For patients with ICAS, the risk of stroke is highly related to the histopathology of atheromatous plaques. Therefore, characterizing the morphology and composition of plaques in ICAS may help to predict the risk of stroke occurrence and allow the adoption of preventive or therapeutic management to prevent such life-threatening events. OCT, with a resolution of 10μm, may provide more reliable information in characterizing atheromatous plagues.

This study aims to get a better insight into the value of OCT in evaluating the vessel wall structure and therefore guiding the interventional therapy of ICAS. In addition, the clinical and biological information will be included to achieve correlation analysis so as to get biomarkers subject to various plaque characteristics.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
400 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis: a Prospective Registry Study (OCT-ICAS)
Actual Study Start Date :
Mar 15, 2020
Anticipated Primary Completion Date :
Dec 31, 2026
Anticipated Study Completion Date :
Dec 31, 2027

Arms and Interventions

Arm Intervention/Treatment
Optical Coherence Tomography (OCT)

OCT and other classical imaging evaluation such as Transcranial Color Doppler (TCCD) and High resolution-MRI will be performed. The tailored treatment (such as anti-thrombotic management, post-dilation, et al) will be considered when specific plaque characteristics (including but not limited to in situ thrombus formation, macrocacilfication, et al), were observed under OCT.

Diagnostic Test: Optical Coherence Tomography
Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography

Procedure: Percutaneous transluminal angioplasty and stenting
Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.

Non-Optical Coherence Tomography (N-OCT)

Classical imaging evaluation such as TCCD and High resolution-MRI will be performed, followed by standard percutaneous transluminal angioplasty and stenting.

Procedure: Percutaneous transluminal angioplasty and stenting
Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.

Outcome Measures

Primary Outcome Measures

  1. Safety outcomes: short-term death or stroke [30 days after enrollment]

    We defined 'short-term' as the periprocedural period, or mean follow-up time less than or equal to three months after enrollment. Stroke was identified in the vascular territory of the stenosed vessel, either ischaemic or haemorrhagic. We defined death or stroke as a composite of death of any cause or non-fatal stroke of any type in any territory.

Secondary Outcome Measures

  1. Death or stroke [1 year after enrollment]

    (long term; more than three months)

  2. Ipsilateral stroke [1 year after enrollment]

    (same territory as the index stenosis)

  3. Type of recurrent event [1 year after enrollment]

    (TIA, ischaemic stroke, haemorrhagic stroke)

  4. Death [1 year after enrollment]

    (long term; more than three months)

  5. Restenosis [1 year after enrollment]

    (≥ 50%) of the involved vessel documented by conventional cerebral angiography

  6. Dependency [1 year after enrollment]

    Modified Rankin Scale or equivalent

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Symptomatic ICAS. Participants with ICAS with a transient ischaemic attack (TIA) or stroke attributable to the territory of the stenotic artery were defined as symptomatic. A TIA was defined as a transient episode of neurological dysfunction (focal weakness or language disturbance, transient monocular blindness, or required assistance in walking) caused by focal brain or retinal ischaemia that lasted for at least 10 minutes but resolved within 24 hours

  • Stenotic degree ≥ 50%, measured by digital subtraction angiography

  • The stenosis must located in at least one major intracranial artery (internal carotid artery, vertebral artery, middle cerebral artery, or basilar artery)

Exclusion Criteria:
  • Arteriovenous Malformation

  • Aneurysm

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xuanwu Hospital, Capital Medical University Beijing Beijing China 100005

Sponsors and Collaborators

  • jiaoliqun

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
jiaoliqun, Director, Department of Interventional Neuroradiology, Principal Investigator, Clinical Professor, Xuanwu Hospital, Beijing
ClinicalTrials.gov Identifier:
NCT05550077
Other Study ID Numbers:
  • OCT-ICAS
First Posted:
Sep 22, 2022
Last Update Posted:
Sep 23, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by jiaoliqun, Director, Department of Interventional Neuroradiology, Principal Investigator, Clinical Professor, Xuanwu Hospital, Beijing
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 23, 2022